Frontlight ResearchEarly access
CompletedPhase 4
A randomized trial investigating the superiority of TDM-optimized teicoplanin dosing versus standard of care
Key facts
- Who runs it
- Stichting Radboud University Medical Center
- Where
- Netherlands1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- Phase
- Phase 4
- People taking part
- 74 people enrolled
- Started
- 17 Aug 2023
- Ended
- 20 Feb 2026
- Type of study
- Interventional
- Record updated
- 1 July 2025
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 8 criteriaShow less
Who can take part
- The patient is admitted to the Radboudumc
- The patient is at least 18 years old on the day of inclusion
- The patient is treated with teicoplanin as part of standard care
- The patient or a representative is willing to sign the Informed Consent Form
Who cannot take part
- The patient has previously participated in this study
- Expected duration of teicoplanin therapy is less than 5 days
- The patient receives any form of RRT other than CVVHD / CVVHDF
- Pregnant individuals
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
To investigate target attainment at 5 days after treatment initiation in patients receiving TDM- guided dosing versus patients receiving standard dosing.
Data and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Record updated
- 1 July 2025